Leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, Catalent Pharma Solutions Inc (Somerset, NJ), earlier today announced that it has acquired the remaining stake in Redwood Bioscience Inc.(Emeryville, CA), and the SMARTag Antibody-Drug Conjugate (ADC) technology platform. This is the company’s first acquisition since its IPO in July.
The acquisition follows the successful achievement of in vivo and in vitro proof of concept milestones, recent compelling in vivo toxicology data, and strong customer interest in the SMARTag technology. Under the terms of the agreement, Catalent acquires the remaining outstanding shares of Redwood. Redwood’s team in Emeryville, CA, will become part of Catalent’s network under the leadership of Redwood President, CSO and Founder, David Rabuka, PhD, who will continue to advance the development of the SMARTag technology as part of Catalent’s growing Biologics business.
In April 2013 Catalent announced that it had acquired an exclusive license to market the SMARTag technology and has subsequently collaborated with Redwood for the ongoing development and marketing of the platform.
Commenting on this acquisition, John Chiminski, President and CEO, Catalent Pharma Solutions, said: “This acquisition brings a highly differentiated technology in the SMARTag platform, as well as a high caliber and innovative scientific team. It is aligned with our strategic focus on innovation and technology, and further demonstrates our ability to strengthen our position in key growth markets through internal and external investments.”
Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies added, “In vivo toxicology studies have demonstrated that an ADC generated using the SMARTag platform has a better toxicity profile than a conventional ADC, and with efficacy studies, point to an improved therapeutic index. This acquisition builds on our recent investment in a state-of-the-art Biomanufacturing facility and underpins our strategy of investing in innovative technologies and differentiated solutions in the biologics space.”
One problem with current ADC technology is the difficulty creating conjugates with a uniform drug to antibody ratio and consistent payload placement on the antibody. The novel, site-specific SMARTag technology enables the generation of homogenous bioconjugates, engineered to improve performance and ease of manufacturing. Combined with Catalent’s proprietary GPEx® cell line expression system, its new state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin, and broad range of analytical and fill-finish services, this latest investment marks a further expansion of Catalent’s capabilities to help customers develop more and better biologics treatments.
Published in: Catalent Pharma Solutions Inc website